Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Unfer V, Facchinetti F, Orru B, Giordani B, Nestler J
Published in Endocrine Connections
Methodology
Meta-analysis of randomised controlled trials of myo-inositol, alone or with D-chiro-inositol, in women with polycystic ovary syndrome, pooling hormonal and metabolic endpoints.
Key Findings
Myo-inositol supplementation significantly reduced fasting insulin and HOMA index and improved androgen profiles in women with PCOS; effects on reproductive endpoints were less consistent.
Conclusions
Myo-inositol reliably improves insulin resistance markers in PCOS.
Limitations
Small heterogeneous trials, variable dosing and co-supplementation, several trials with industry ties.
Supplements Studied
Myo-inositol supplementation significantly reduced fasting insulin and HOMA index and improved androgen profiles in women with PCOS.
Outcomes Measured
Myo-inositol improved insulin and androgen profiles underlying ovulatory dysfunction.
Myo-inositol improved hormonal parameters including androgen levels in women with PCOS.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Academic with industry-affiliated authors
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.